Literature DB >> 1327805

The vasorelaxant effect of evodiamine in rat isolated mesenteric arteries: mode of action.

W F Chiou1, C J Chou, A Y Shum, C F Chen.   

Abstract

The roles of the endothelium, Ca2+ and K+ fluxes in the evodiamine-induced attenuation of vascular contractile responses to vasoactive agents were examined. The results showed that: (1) in rat mesenteric artery rings, evodiamine elicited a concentration-dependent attenuation in the contractile response generated by phenylephrine. The inhibitory potency was greater for intact than for endothelium-denuded preparations. Thus, the vasodilator action of evodiamine appeared to be partially endothelium-interactive (dependent). (2) Evodiamine pretreatment had a greater inhibitory effect on the phenylephrine-induced tonic contraction (via Ca2+ influx) than on the phasic contraction (via Ca2+ release). In addition, evodiamine was more potent to inhibit the restoration by CaCl2 of contractile responses to phenylephrine than a potassium depolarizing solution in media that had been kept calcium-free. These results suggest that block of the Ca2+ influx through receptor-mediated Ca2+ channels may be the major mechanism underlying the vasodilator effect of evodiamine. (3) A K+ channel blocker, tetraethylammonium, almost completely abolished the vasodilatation induced by minoxidil (a known K+ channel opener) but not evodiamine. The possible involvement of K+ channel activation of the vasodilator effect produced by evodiamine was therefore excluded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1327805     DOI: 10.1016/0014-2999(92)90039-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:  Shu-min Yuan; Kai Gao; Dong-mei Wang; Xiong-zhi Quan; Jiang-ning Liu; Chun-mei Ma; Chuan Qin; Lian-feng Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  Potential contribution of vasoconstriction to suppression of heat loss and homeothermic regulation in UCP1-deficient mice.

Authors:  Youxue Wang; Kazuhiro Kimura; Ken-ichi Inokuma; Masayuki Saito; Yasuhide Kontani; Yoshinori Kobayashi; Nozomu Mori; Hitoshi Yamashita
Journal:  Pflugers Arch       Date:  2006-01-05       Impact factor: 3.657

3.  Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis.

Authors:  Wei-Qing Rang; Yan-Hua Du; Chang-Ping Hu; Feng Ye; Gui-Shan Tan; Han-Wu Deng; Yuan-Jian Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

4.  Preparation of evodiamine solid dispersions and its pharmacokinetics.

Authors:  H Xu; T Zhang; H Yang; X Xiao; Y Bian; D Si; C Liu
Journal:  Indian J Pharm Sci       Date:  2011-05       Impact factor: 0.975

5.  Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.

Authors:  Ting Wang; Tatsuya Kusudo; Tamaki Takeuchi; Yukari Yamashita; Yasuhide Kontani; Yuko Okamatsu; Masayuki Saito; Nozomu Mori; Hitoshi Yamashita
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

6.  Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis.

Authors:  Xiaodong Bai; Hai Meng; Lifeng Ma; Ai Guo
Journal:  Oncol Lett       Date:  2014-12-11       Impact factor: 2.967

7.  Evodiamine inhibits PDGF‑BB‑induced proliferation of rat vascular smooth muscle cells through the suppression of cell cycle progression and oxidative stress.

Authors:  Xie Ge; Si-Yu Chen; Mei Liu; Ting-Ming Liang; Chang Liu
Journal:  Mol Med Rep       Date:  2016-10-05       Impact factor: 2.952

8.  Combination of berberine and evodiamine inhibits intestinal cholesterol absorption in high fat diet induced hyperlipidemic rats.

Authors:  Xin Zhou; Fengying Ren; Hong Wei; Liyun Liu; Tao Shen; Shijun Xu; Jiangping Wei; Jiayue Ren; Hengfan Ni
Journal:  Lipids Health Dis       Date:  2017-12-11       Impact factor: 3.876

9.  Low-cytotoxic synthetic bromorutaecarpine exhibits anti-inflammation and activation of transient receptor potential vanilloid type 1 activities.

Authors:  Chi-Ming Lee; Jiun-An Gu; Tin-Gan Rau; Che-Hsiung Yang; Wei-Chi Yang; Shih-Hao Huang; Feng-Yen Lin; Chun-Mao Lin; Sheng-Tung Huang
Journal:  Biomed Res Int       Date:  2013-11-28       Impact factor: 3.411

10.  Evodiamine Attenuates PDGF-BB-Induced Migration of Rat Vascular Smooth Muscle Cells through Activating PPARγ.

Authors:  Xie Ge; Siyu Chen; Mei Liu; Tingming Liang; Chang Liu
Journal:  Int J Mol Sci       Date:  2015-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.